- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Devic’s Syndrome (Neuromyelitis Optica) Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Devic’s Syndrome (Neuromyelitis Optica) Treatment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospitals accounting for % of the Devic’s Syndrome (Neuromyelitis Optica) Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Eculizumab segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Devic’s Syndrome (Neuromyelitis Optica) Treatment include Alexion Pharmaceuticals, Inc., Teva Pharmaceuticals, Fresenius Kabi AG, Pharmacia & Upjohn (a subsidary of Pfizer), and Lupin Ltd., etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Devic’s Syndrome (Neuromyelitis Optica) Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Eculizumab
Methylprednisolone
Azathioprine
Mycophenolate Mofetil
Rituximab
Market segment by Application, can be divided into
Hospitals
Clinic
Others
Market segment by players, this report covers
Alexion Pharmaceuticals, Inc.
Teva Pharmaceuticals
Fresenius Kabi AG
Pharmacia & Upjohn (a subsidary of Pfizer)
Lupin Ltd.
Sagent Pharmaceuticals, Inc.
Zydus Pharmaceuticals, Inc.
Sandoz Inc. (Novartis)
Alkem Laboratories Ltd.
Mylan Pharmaceuticals, Inc.
Hoffmann-La Roche/ Chugai Pharmaceutical
MedImmune LLC
RemeGen, Ltd.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Devic’s Syndrome (Neuromyelitis Optica) Treatment product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Devic’s Syndrome (Neuromyelitis Optica) Treatment, with revenue, gross margin and global market share of Devic’s Syndrome (Neuromyelitis Optica) Treatment from 2019 to 2022.
Chapter 3, the Devic’s Syndrome (Neuromyelitis Optica) Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Devic’s Syndrome (Neuromyelitis Optica) Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Devic’s Syndrome (Neuromyelitis Optica) Treatment research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1 Market Overview
1.1 Product Overview and Scope of Devic’s Syndrome (Neuromyelitis Optica) Treatment
1.2 Classification of Devic’s Syndrome (Neuromyelitis Optica) Treatment by Type
1.2.1 Overview: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type in 2021
1.2.3 Eculizumab
1.2.4 Methylprednisolone
1.2.5 Azathioprine
1.2.6 Mycophenolate Mofetil
1.2.7 Rituximab
1.3 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market by Application
1.3.1 Overview: Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size & Forecast
1.5 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast by Region
1.5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region, (2017-2022)
1.5.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Prospect (2017-2028)
1.5.4 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Prospect (2017-2028)
1.5.6 South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers
1.6.2 Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints
1.6.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Trends Analysis
2 Company Profiles
2 Company Profiles
2.1 Alexion Pharmaceuticals, Inc.
2.1.1 Alexion Pharmaceuticals, Inc. Details
2.1.2 Alexion Pharmaceuticals, Inc. Major Business
2.1.3 Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
2.1.4 Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Alexion Pharmaceuticals, Inc. Recent Developments and Future Plans
2.2 Teva Pharmaceuticals
2.2.1 Teva Pharmaceuticals Details
2.2.2 Teva Pharmaceuticals Major Business
2.2.3 Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
2.2.4 Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Teva Pharmaceuticals Recent Developments and Future Plans
2.3 Fresenius Kabi AG
2.3.1 Fresenius Kabi AG Details
2.3.2 Fresenius Kabi AG Major Business
2.3.3 Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
2.3.4 Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Fresenius Kabi AG Recent Developments and Future Plans
2.4 Pharmacia & Upjohn (a subsidary of Pfizer)
2.4.1 Pharmacia & Upjohn (a subsidary of Pfizer) Details
2.4.2 Pharmacia & Upjohn (a subsidary of Pfizer) Major Business
2.4.3 Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
2.4.4 Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Pharmacia & Upjohn (a subsidary of Pfizer) Recent Developments and Future Plans
2.5 Lupin Ltd.
2.5.1 Lupin Ltd. Details
2.5.2 Lupin Ltd. Major Business
2.5.3 Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
2.5.4 Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Lupin Ltd. Recent Developments and Future Plans
2.6 Sagent Pharmaceuticals, Inc.
2.6.1 Sagent Pharmaceuticals, Inc. Details
2.6.2 Sagent Pharmaceuticals, Inc. Major Business
2.6.3 Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
2.6.4 Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Sagent Pharmaceuticals, Inc. Recent Developments and Future Plans
2.7 Zydus Pharmaceuticals, Inc.
2.7.1 Zydus Pharmaceuticals, Inc. Details
2.7.2 Zydus Pharmaceuticals, Inc. Major Business
2.7.3 Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
2.7.4 Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Zydus Pharmaceuticals, Inc. Recent Developments and Future Plans
2.8 Sandoz Inc. (Novartis)
2.8.1 Sandoz Inc. (Novartis) Details
2.8.2 Sandoz Inc. (Novartis) Major Business
2.8.3 Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
2.8.4 Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Sandoz Inc. (Novartis) Recent Developments and Future Plans
2.9 Alkem Laboratories Ltd.
2.9.1 Alkem Laboratories Ltd. Details
2.9.2 Alkem Laboratories Ltd. Major Business
2.9.3 Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
2.9.4 Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Alkem Laboratories Ltd. Recent Developments and Future Plans
2.10 Mylan Pharmaceuticals, Inc.
2.10.1 Mylan Pharmaceuticals, Inc. Details
2.10.2 Mylan Pharmaceuticals, Inc. Major Business
2.10.3 Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
2.10.4 Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Mylan Pharmaceuticals, Inc. Recent Developments and Future Plans
2.11 Hoffmann-La Roche/ Chugai Pharmaceutical
2.11.1 Hoffmann-La Roche/ Chugai Pharmaceutical Details
2.11.2 Hoffmann-La Roche/ Chugai Pharmaceutical Major Business
2.11.3 Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
2.11.4 Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Hoffmann-La Roche/ Chugai Pharmaceutical Recent Developments and Future Plans
2.12 MedImmune LLC
2.12.1 MedImmune LLC Details
2.12.2 MedImmune LLC Major Business
2.12.3 MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
2.12.4 MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 MedImmune LLC Recent Developments and Future Plans
2.13 RemeGen, Ltd.
2.13.1 RemeGen, Ltd. Details
2.13.2 RemeGen, Ltd. Major Business
2.13.3 RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
2.13.4 RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 RemeGen, Ltd. Recent Developments and Future Plans
3 Market Competition, by Players
3 Market Competition, by Players
3.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Players Market Share in 2021
3.2.2 Top 10 Devic’s Syndrome (Neuromyelitis Optica) Treatment Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Devic’s Syndrome (Neuromyelitis Optica) Treatment Players Head Office, Products and Services Provided
3.4 Devic’s Syndrome (Neuromyelitis Optica) Treatment Mergers & Acquisitions
3.5 Devic’s Syndrome (Neuromyelitis Optica) Treatment New Entrants and Expansion Plans
4 Market Size Segment by Type
4 Market Size Segment by Type
4.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Market Share by Type (2017-2022)
4.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5 Market Size Segment by Application
5.1 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Application (2017-2022)
5.2 Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6 North America by Country, by Type, and by Application
6.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2017-2028)
6.2 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2017-2028)
6.3 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
6.3.1 North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2017-2028)
6.3.2 United States Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
6.3.3 Canada Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
6.3.4 Mexico Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7 Europe by Country, by Type, and by Application
7.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2017-2028)
7.2 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2017-2028)
7.3 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
7.3.1 Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2017-2028)
7.3.2 Germany Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
7.3.3 France Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
7.3.5 Russia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
7.3.6 Italy Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2017-2028)
8.2 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2017-2028)
8.3 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Region
8.3.1 Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Region (2017-2028)
8.3.2 China Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
8.3.3 Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
8.3.4 South Korea Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
8.3.5 India Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
8.3.7 Australia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9 South America by Country, by Type, and by Application
9.1 South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2017-2028)
9.2 South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2017-2028)
9.3 South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
9.3.1 South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2017-2028)
9.3.2 Brazil Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
9.3.3 Argentina Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2017-2028)
10.2 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2017-2028)
10.3 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size by Country
10.3.1 Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2017-2028)
10.3.2 Turkey Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
10.3.4 UAE Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
11 Research Findings and Conclusion
12 Appendix
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of Tables
Table 1. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) by Region (2017-2022)
Table 5. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Region (2023-2028)
Table 6. Alexion Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Alexion Pharmaceuticals, Inc. Major Business
Table 8. Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
Table 9. Alexion Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Teva Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 11. Teva Pharmaceuticals Major Business
Table 12. Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
Table 13. Teva Pharmaceuticals Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Fresenius Kabi AG Corporate Information, Head Office, and Major Competitors
Table 15. Fresenius Kabi AG Major Business
Table 16. Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
Table 17. Fresenius Kabi AG Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Pharmacia & Upjohn (a subsidary of Pfizer) Corporate Information, Head Office, and Major Competitors
Table 19. Pharmacia & Upjohn (a subsidary of Pfizer) Major Business
Table 20. Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
Table 21. Pharmacia & Upjohn (a subsidary of Pfizer) Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Lupin Ltd. Corporate Information, Head Office, and Major Competitors
Table 23. Lupin Ltd. Major Business
Table 24. Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
Table 25. Lupin Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Sagent Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 27. Sagent Pharmaceuticals, Inc. Major Business
Table 28. Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
Table 29. Sagent Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Zydus Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 31. Zydus Pharmaceuticals, Inc. Major Business
Table 32. Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
Table 33. Zydus Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Sandoz Inc. (Novartis) Corporate Information, Head Office, and Major Competitors
Table 35. Sandoz Inc. (Novartis) Major Business
Table 36. Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
Table 37. Sandoz Inc. (Novartis) Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Alkem Laboratories Ltd. Corporate Information, Head Office, and Major Competitors
Table 39. Alkem Laboratories Ltd. Major Business
Table 40. Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
Table 41. Alkem Laboratories Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Mylan Pharmaceuticals, Inc. Corporate Information, Head Office, and Major Competitors
Table 43. Mylan Pharmaceuticals, Inc. Major Business
Table 44. Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
Table 45. Mylan Pharmaceuticals, Inc. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Hoffmann-La Roche/ Chugai Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 47. Hoffmann-La Roche/ Chugai Pharmaceutical Major Business
Table 48. Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
Table 49. Hoffmann-La Roche/ Chugai Pharmaceutical Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. MedImmune LLC Corporate Information, Head Office, and Major Competitors
Table 51. MedImmune LLC Major Business
Table 52. MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
Table 53. MedImmune LLC Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. RemeGen, Ltd. Corporate Information, Head Office, and Major Competitors
Table 55. RemeGen, Ltd. Major Business
Table 56. RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Product and Solutions
Table 57. RemeGen, Ltd. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 59. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 60. Breakdown of Devic’s Syndrome (Neuromyelitis Optica) Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 61. Devic’s Syndrome (Neuromyelitis Optica) Treatment Players Head Office, Products and Services Provided
Table 62. Devic’s Syndrome (Neuromyelitis Optica) Treatment Mergers & Acquisitions in the Past Five Years
Table 63. Devic’s Syndrome (Neuromyelitis Optica) Treatment New Entrants and Expansion Plans
Table 64. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) by Type (2017-2022)
Table 65. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Type (2017-2022)
Table 66. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Forecast by Type (2023-2028)
Table 67. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2017-2022)
Table 68. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Forecast by Application (2023-2028)
Table 69. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 70. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 71. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 72. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 73. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 74. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2023-2028) & (USD Million)
Table 75. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 76. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 77. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 78. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 79. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 80. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2023-2028) & (USD Million)
Table 81. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 82. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 83. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 84. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 85. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Region (2017-2022) & (USD Million)
Table 86. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Region (2023-2028) & (USD Million)
Table 87. South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 88. South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 89. South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 90. South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 91. South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 92. South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2023-2028) & (USD Million)
Table 93. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2017-2022) & (USD Million)
Table 94. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Type (2023-2028) & (USD Million)
Table 95. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2017-2022) & (USD Million)
Table 96. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Application (2023-2028) & (USD Million)
Table 97. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2017-2022) & (USD Million)
Table 98. Middle East & Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Devic’s Syndrome (Neuromyelitis Optica) Treatment Picture
Figure 2. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Type in 2021
Figure 3. Eculizumab
Figure 4. Methylprednisolone
Figure 5. Azathioprine
Figure 6. Mycophenolate Mofetil
Figure 7. Rituximab
Figure 8. Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Application in 2021
Figure 9. Hospitals Picture
Figure 10. Clinic Picture
Figure 11. Others Picture
Figure 12. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 13. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Forecast (2017-2028) & (USD Million)
Figure 14. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Region (2017-2028)
Figure 15. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Region in 2021
Figure 16. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Drivers
Figure 22. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Restraints
Figure 23. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Trends
Figure 24. Alexion Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 25. Teva Pharmaceuticals Recent Developments and Future Plans
Figure 26. Fresenius Kabi AG Recent Developments and Future Plans
Figure 27. Pharmacia & Upjohn (a subsidary of Pfizer) Recent Developments and Future Plans
Figure 28. Lupin Ltd. Recent Developments and Future Plans
Figure 29. Sagent Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 30. Zydus Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 31. Sandoz Inc. (Novartis) Recent Developments and Future Plans
Figure 32. Alkem Laboratories Ltd. Recent Developments and Future Plans
Figure 33. Mylan Pharmaceuticals, Inc. Recent Developments and Future Plans
Figure 34. Hoffmann-La Roche/ Chugai Pharmaceutical Recent Developments and Future Plans
Figure 35. MedImmune LLC Recent Developments and Future Plans
Figure 36. RemeGen, Ltd. Recent Developments and Future Plans
Figure 37. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Players in 2021
Figure 38. Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 39. Global Top 3 Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share in 2021
Figure 40. Global Top 10 Players Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share in 2021
Figure 41. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 42. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Type in 2021
Figure 43. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share Forecast by Type (2023-2028)
Figure 44. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Share by Application in 2021
Figure 45. Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Share Forecast by Application (2023-2028)
Figure 46. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Type (2017-2028)
Figure 47. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Application (2017-2028)
Figure 48. North America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Country (2017-2028)
Figure 49. United States Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Canada Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Mexico Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Type (2017-2028)
Figure 53. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Application (2017-2028)
Figure 54. Europe Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Country (2017-2028)
Figure 55. Germany Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. France Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. United Kingdom Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Russia Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Italy Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Type (2017-2028)
Figure 61. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Application (2017-2028)
Figure 62. Asia-Pacific Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Region (2017-2028)
Figure 63. China Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. Japan Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. South Korea Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. India Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Southeast Asia Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Australia Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Type (2017-2028)
Figure 70. South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Application (2017-2028)
Figure 71. South America Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Country (2017-2028)
Figure 72. Brazil Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Argentina Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Type (2017-2028)
Figure 75. Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Sales Market Share by Application (2017-2028)
Figure 76. Middle East and Africa Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue Market Share by Country (2017-2028)
Figure 77. Turkey Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Saudi Arabia Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 79. UAE Devic’s Syndrome (Neuromyelitis Optica) Treatment Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Methodology
Figure 81. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
